Taipei Medical University Institutional Repository:Item 987654321/6829
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 45069/58245 (77%)
Visitors : 2369151      Online Users : 164
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://libir.tmu.edu.tw/handle/987654321/6829


    Title: 包含水難溶性藥物之固態化自發性微乳化遞藥系統之處方開發與評估
    Formulation Development and Evaluation of Solidified Self-Microemulsifying Drug Delivery Systems Containing a Poorly Water-Soluble Drug
    Authors: 黃煒裕
    Wei-Yu Huang
    Contributors: 藥學研究所
    Keywords: 微乳劑
    固型劑
    自發性微乳化遞藥系統
    奈米晶體
    microemulsions
    solid carriers
    SMEDDS
    nanocrystals
    Date: 2009
    Issue Date: 2009-09-15 15:40:52 (UTC+8)
    Abstract: 自發性微乳化遞藥系統(SMEDDSs)在胃腸道中接觸水相並且靠著輕微的攪動或蠕動後,會自然乳化成為澄清且均勻的微胞流體。自發性微乳化系統通常由油相、界面活性劑、助界面活性劑以及藥物所組成,相對於水難溶性化合物之傳統劑型是個具有發展潛力的替代劑型。在本研究中,fenofibrate為親脂性模式藥物,溶於正乳酸丁酯再以聚山梨酸酯(Tween 20與Tween 80)以及一些醇類(乙醇,正丙醇與聚乙二醇)混合後,以媒液(去離子水或醣類/固型劑水溶液)進行控速稀釋,再將溶液真空冷凍乾燥。初步目的為利用擬三成分相圖建立處方,然後分析凍乾前後系統粒子的大小,期望重行分散於水相後還有良好的微小粒徑(奈米層級),之後再評估並調整製程參數。
    很多的藥學乾燥技術皆可被應用於製備固態化微乳劑。在乾燥過程前會先加入上述的親水性固型劑(抗凍劑),因為它能藉由立體障礙及斥力來防止粒子或微胞間的大量凝集,並且能維持原本液態自發性微乳化劑型的乳化效能。本實驗所用到的固型劑為lactose, mannitol, glucose, sucrose and trehalose。發展固態劑型主要的難度在於如何確保真空冷凍乾燥後粒子重行分散的安定性。因為凍乾後粒子彼此凝集的關係,許多固化系統的粒徑皆大於2μm,而當以0.5%(w/w) sodium lauryl sulfate(SLS)溶液進行分散,粒徑可以在凍乾後30分鐘到90分鐘維持穩定以及在許多實驗組中維持在500nm~2μm的粒徑範圍內。這在50%固型劑/Ethanol/Tween 80組別中為最明顯,平均從水相中的4800nm粒徑下降至SLS溶液中的1700nm粒徑左右,而該組中以Lactose當固型劑更能使各處方平均粒徑減至900nm ~ 1000nm。

    最後還進行處方晶型的研究。而從上述研究中建立固態化水難溶性藥物之自發性微乳化遞藥系統的最佳製備方式,可在往後將此可稀釋的遞藥系統以奈米級包覆材質包覆的技術提供試驗基礎與模式。

    Self-microemulsifying drug delivery systems (SMEDDSs), which can be self-emulsified into a translucent and isotropic fluid in aqueous medium under gentle digestive motility in the gastrointestinal tract, usually consisting of a mixture of oils, surfactants, cosurfactants and drugs, represent a promising alternative to traditional formulations of poorly water-soluble Compounds. In the present study, a model lipophilic drug, Fenofibrate, is formulated in n-butyl L-lactate, polysorbates (Tween 20 and Tween 80) and a number of alcohols (ethanol, 1-propanol and PEG 600) as well, then diluted with mediums (dH2O or solution of carbohydrates/solid carriers)at certain rate prior to the freeze drying process. Our initiative objective is to construct pseudo-ternary diagram phase for formulations and analyze the particle size of SMEDDS before/after lyophilization in hope of the smaller particle size (nanoscale) redispersed in aqueous phases following drying, then turn to evaluate the systems and adjust the procedural parameters.

    A plenty of drying technology had been employed to prepare dry microemulsions by removing water from an ordinary microemulsions containing a water soluble solid carrier (or cryoprotectant) which could not only prevent particles or micelles from large aggregation by steric hindrance and repulsive force but preserve microemulsification performance the same as that of liquid self- microemulsifying drug delivery systems. On the study, solid carriers in use include lactose, mannitol, glucose, sucrose and trehalose. The main difficulties with a solidified formulation lied in the stability of particulate redispersibility after the drying step. As consequence of agglomeration, the particle size was much larger than 2μm though; when adding solution of 0.5%(w/w) SLS (sodium lauryl sulfate) to redisperse the solid systems, the particle could retain stable in size from 30mins to 90mins following drying and reach smaller size of 500nm~2μm in most experimental groups. In groups with 50% solid carrier/ethanol/Tween 80,it was most obvious that the range of size reduction could reach in average from 4800nm in water phase to about 1700nm in SLS solution;when it came to Lactose as a solid carrier, the system particles could even be reduced in mean size of 900nm ~ 1000nm in all formulas.
    Furthermore, we proceed an observation of crystalline structures of formulations. Chances are that we can establish the most optimized preparation method of solidified self-microemulsifying drug delivery containing a poorly water-soluble compound from a set of the above evaluations. On the other hand, our study can provide a foundation and a model for pharmaceutical technology of the dilutable drug delivery systems combined with nanoparticulate polymers in the near future.
    Data Type: thesis
    Appears in Collections:[School of Pharmacy] Dissertation/Thesis

    Files in This Item:

    File Description SizeFormat
    摘要.doc30KbMicrosoft Word90View/Open
    摘要.pdf126KbAdobe PDF277View/Open
    摘要.ppt146KbMicrosoft Powerpoint275View/Open
    摘要.ps728KbPostscript60View/Open


    All items in TMUIR are protected by copyright, with all rights reserved.


    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback